作者
Raghavendra Rao,S. Varghese,Farmud Ansari,A. Koneti Rao,Eric Meng,Mohammad El‐Diasty
摘要
•The current risk scores may underestimate surgical risk in higher-risk patients who underwent cardiac surgery. •Preoperative natriuretic peptides predict adverse outcomes after cardiac surgery, such as mortality, heart failure, kidney injury, and intensive care unit length of stay. •The incorporation of these biomarkers in clinical practice may improve the effectiveness of the current risk stratification strategies. The increasing global burden of cardiovascular disease, particularly, in the aging population, has led to an increase in high-risk cardiac surgical procedures. The current preoperative risk stratification scores, such as the European System for Cardiac Operative Risk Evaluation and the Society for Thoracic Surgeons score, have limitations in their predictive accuracy and tend to underestimate the mortality risk in higher-risk populations. This systematic review aimed to evaluate the utility of natriuretic peptides, brain natriuretic peptide (BNP) and its precursor prohormone (N-terminal prohormone BNP), as predictive biomarkers for adverse outcomes after cardiac surgery. A comprehensive search strategy was performed, and 63 studies involving 40,667 patients who underwent major cardiac operations were included for data extraction. Preoperative levels of BNP and N-terminal prohormone BNP seemed to be associated with an increased risk of short- and long-term mortality, postoperative heart failure, kidney injury, and length of intensive care unit stay. However, their predictive value for postoperative arrhythmias and myocardial infarction was less established. Our findings suggest that natriuretic peptides may play an important role in risk prediction in patients who underwent cardiac surgery. The addition of these biomarkers to the existing clinical risk stratification strategies may enhance their predictive accuracy. However, this needs to be endorsed by data derived from wide-scale clinical trials. The increasing global burden of cardiovascular disease, particularly, in the aging population, has led to an increase in high-risk cardiac surgical procedures. The current preoperative risk stratification scores, such as the European System for Cardiac Operative Risk Evaluation and the Society for Thoracic Surgeons score, have limitations in their predictive accuracy and tend to underestimate the mortality risk in higher-risk populations. This systematic review aimed to evaluate the utility of natriuretic peptides, brain natriuretic peptide (BNP) and its precursor prohormone (N-terminal prohormone BNP), as predictive biomarkers for adverse outcomes after cardiac surgery. A comprehensive search strategy was performed, and 63 studies involving 40,667 patients who underwent major cardiac operations were included for data extraction. Preoperative levels of BNP and N-terminal prohormone BNP seemed to be associated with an increased risk of short- and long-term mortality, postoperative heart failure, kidney injury, and length of intensive care unit stay. However, their predictive value for postoperative arrhythmias and myocardial infarction was less established. Our findings suggest that natriuretic peptides may play an important role in risk prediction in patients who underwent cardiac surgery. The addition of these biomarkers to the existing clinical risk stratification strategies may enhance their predictive accuracy. However, this needs to be endorsed by data derived from wide-scale clinical trials. Risk Stratification Before Cardiac SurgeryAmerican Journal of CardiologyVol. 210PreviewCardiac surgery, a commonly performed procedure globally, may be associated with significant mortality and morbidity rates. Based on the 2023 American Heart Association update of the heart disease and stroke statistics, an estimated 202,000 coronary artery bypass surgeries (CABGs), were performed for inpatients in the United States.1 Based on these large volumes of procedures, careful selection of surgical candidates is, key to optimizing morbidity and mortality outcomes, and optimum risk stratification is indicated to inform this decision-making process. Full-Text PDF